How bladder cancer originates and progresses has been illuminated as never before in a study led by researchers at Weill Cornell Medicine and the New York Genome Center. The researchers found that antiviral enzymes that mutate the DNA of normal and cancer cells are key promoters of early bladder cancer development, and that standard chemotherapy is also a potent source of mutations. The researchers also discovered that overactive genes within abnormal circular DNA structures in tumor cells genes drive bladder cancer resistance to therapy. These findings are novel insights into bladder cancer biology and point to new therapeutic strategies for this difficult-to-treat cancer.
The study, published Sept. 9 in Nature, focused on the main form of bladder cancer, urothelial carcinoma, which originates from cells that line the bladder, urethra, and tubes that drain urine from the kidneys. The researchers examined malignant and pre-malignant urothelial cells taken from the same set of patients at different disease stages. They used whole-genome sequencing and advanced computational methods to map common DNA mutations, complex structural variants, and their timing.
"Our findings define new fundamental mechanisms driving bladder cancer evolution—mechanisms that we can now think about targeting with therapies," said co-senior author Dr. Bishoy Faltas, the Gellert Family–John P. Leonard MD Research Scholar in Hematology and Medical Oncology and an associate professor of medicine and of cell and developmental biology at Weill Cornell Medicine, and an oncologist at NewYork-Presbyterian/Weill Cornell Medical Center.
Dr. Nicolas Robine, director of computational biology at the New York Genome Center, and Dr. Olivier Elemento, director of the Englander Institute for Precision Medicine and a professor of physiology and biophysics at Weill Cornell Medicine, also led the study with Dr. Faltas. The co-first authors were Duy Nguyen, a technician in the Faltas Laboratory (now a doctoral student at Harvard Medical School); William Hooper, a bioinformatics scientist at the New York Genome Center; and Dr. Weisi Liu, an instructor in the Faltas Laboratory.
Major Therapeutic Targets Come into Focus
Bladder cancer occurs at the rate of about 80,000 cases per year in the United States. It can be cured with surgery if caught early, but about 30 percent of cases are diagnosed at later stages when it is much harder to treat successfully.
The researchers in the new study found strong evidence that the APOBEC3 enzymes cause early mutations that may help trigger the development of this cancer type. These enzymes evolved to disable infecting retroviruses by editing their viral DNA, though it is known that they can sometimes mutate cells' own DNA.
"The exact role of APOBEC3-induced mutations in cancer initiation hasn't been clear," said Dr. Faltas, who is also the chief research officer at the Englander Institute for Precision Medicine and a member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. "But we found that these mutations appear early in urothelial cancer, occurring even in pre-malignant urothelial tissue." In his lab, Dr. Faltas is focusing on studying the role of these mutagenic enzymes in driving cancer evolution.
The researchers found that cisplatin and other platinum-based chemotherapies cause further prominent bursts of mutations, some of which likely allow urothelial cancer cells to survive better and spread despite treatment.
A third major finding was that urothelial tumors often contain complex rearrangements of their DNA that give rise to circular segments of DNA. These "extra-chromosomal DNAs" (ecDNAs) exist apart from chromosomes in the cell nucleus and can sometimes harbor hundreds of copies of cancer-driving growth genes. The researchers discovered that these ecDNA events persist and become more complex, incorporating new DNA segments after treatment, suggesting that they drive resistance to therapy.
This prompted the team to experimentally model an ecDNA version of one of these genes, called CCND1, a master regulator of the cell cycle in the laboratory. The results of these experiments confirmed that CCND1 in this extrachromosomal configuration drives treatment resistance.
Altogether, the findings paint a much clearer picture of the factors that trigger and drive urothelial cancer.
"Traditionally, when analyzing tumor genomes, we've used methods that analyze only a tiny fraction of their DNA, but we've come to realize that there's a lot more to discover if we sequence all their DNA and use smart methods to evaluate that data," Dr. Elemento said. "I think this collaboration vindicates that strategy."
The Englander Institute and New York Genome Center researchers are planning larger future collaborative studies to dig even deeper into urothelial cancer biology, for example, doing whole-genome sequencing of DNA along with readouts of gene activity not just in bulk tumor samples but in individual tumor cells.
"Combining those two sets of information at the single-cell level would be tremendously important and interesting," Dr. Robine said.
The researchers also plan to study potential clinical applications of this work. The investigators are hopeful that a new FDA-approved drug targeting the ERBB2 gene product—the HER2 receptor protein, also found on breast tumor cells—will work especially well in urothelial cancer patients with strong signs of ERBB2 ecDNAs. They are also working on finding ways to block ecDNA formation and maintenance.
Many Weill Cornell Medicine physicians and scientists maintain relationships and collaborate with external organizations to foster scientific innovation and provide expert guidance. The institution makes these disclosures public to ensure transparency. For this information, see profiles for Dr. Bishoy Faltas and Dr. Olivier Elemento.
The research reported in this story was supported in part by the National Cancer Institute and the National Center for Advancing Translational Science, both part of the National Institutes of Health, through grant numbers R37CA279737, U01CA260369, UL1TR002384; and the United States Department of Defense through grant number W81XWH-17-1-0539. Additional support was provided by the Starr Cancer Consortium, the Leo & Anne Albert Institute for Bladder Cancer Care and Research, the Translational Research Program in the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine and the New York Genome Center's Polyethnic-1000 Initiative.
